Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.45 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.43 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196635 | 0.98 | KMT2A (0.49) | KMT2AMEN1NLRP3CA12CA2 | |
| SCHEMBL11973878 | 0.96 | KMT2A (0.47) | KMT2AMEN1NLRP3CA12CA2 | |
| SCHEMBL11973371 | 0.96 | KMT2A (0.47) | KMT2AMEN1NLRP3CA12CA2 | |
| Ethane SCHEMBL7405342 | 0.96 | KMT2A (0.47) | KMT2AMEN1NLRP3CA12CA2 | |
| SCHEMBL14067916 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TSHRHTTSMN1; SMN2RAB9A | |
| SCHEMBL1547824 | 0.84 | KMT2A (0.49) | KMT2AMEN1NLRP3CA12CA2 | |
| Hydrochloric Acid SCHEMBL7661504 | 0.83 | KMT2A (0.45) | KMT2AMEN1NLRP3CA12CA2 | |
| Hydrochloric Acid SCHEMBL1961276 | 0.83 | CA2 (0.42) | KMT2AMEN1NLRP3CA12CA2 | |
| Hydrochloric Acid SCHEMBL19555432 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TSHRHTTCYP3A4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3907034 | 0.82 | CHRM5 (0.45) | KMT2ACA12CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478457-B2 | Castration-resistant prostate cancer | NUTECH VENTURES (US) | 2022-10-25 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2349990-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | Pimco 2664 Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-7160902-B2 | Amide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2005049564-A1 | AMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050107355-A1 | Amide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-5245046-A | α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents | THE UPJOHN COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| US-5128346-A | Cholecystokinin antagonists | ABBOTT LABORATORIES (US) | 1992-07-07 | — | — | US | disclosed |
| US-4971978-A | CHOLECYSTOKININ ANTAGONIST, ANALGESICS, CNS, ANALGESICS, AMIDE DERIVATIVES OF QUINOLINE | ABBOTT LABORATORIES | 1990-11-20 | — | — | US | disclosed |
| EP-0375133-A1 | Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents | THE UPJOHN COMPANY (US) | 1990-06-27 | — | — | EP | disclosed |
| WO-1990005721-A1 | ALPHA-AMINO-INDOLE-3-ACETIC ACIDS USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS | THE UPJOHN COMPANY (US) | 1990-05-31 | — | — | WO | disclosed |
| EP-0308885-A1 | Derivatives of d-glutamic acid and d-aspartic acid | ABBOTT LABORATORIES (US) | 1989-03-29 | — | — | EP | disclosed |
| WO-1989002431-A1 | DERIVATIVES OF D-GLUTAMIC ACID AND D-ASPARTIC ACID | ABBOTT LABORATORIES (US) | 1989-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478457-B2 | Castration-resistant prostate cancer | UGDH, G6PD, DPYD | CA2 3829/4885GLA 357/4885OPRM1 3026/4885 |
| US-20050107355-A1 | Amide derivatives and methods of their use | HRH2, SLC10A2, ALPI | CA2 1342/4885GLA 785/4885OPRM1 47/4885 |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | SOST, PSAP, ARSA | CA2 2774/4885GLA 1180/4885OPRM1 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.